Two Sigma Advisers LP Has $5.19 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Two Sigma Advisers LP boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 72.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,100 shares of the medical research company's stock after acquiring an additional 11,800 shares during the quarter. Two Sigma Advisers LP owned approximately 0.05% of Charles River Laboratories International worth $5,187,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. Flagship Harbor Advisors LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $237,000. Blue Trust Inc. raised its position in Charles River Laboratories International by 7.8% during the fourth quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company's stock valued at $398,000 after acquiring an additional 146 shares in the last quarter. KBC Group NV raised its position in Charles River Laboratories International by 0.9% during the fourth quarter. KBC Group NV now owns 85,362 shares of the medical research company's stock valued at $15,758,000 after acquiring an additional 796 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in Charles River Laboratories International by 3.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company's stock valued at $804,000 after acquiring an additional 126 shares in the last quarter. Finally, Forsta AP Fonden raised its position in Charles River Laboratories International by 6.6% during the fourth quarter. Forsta AP Fonden now owns 11,300 shares of the medical research company's stock valued at $2,086,000 after acquiring an additional 700 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded down $1.43 during midday trading on Friday, hitting $136.27. The company had a trading volume of 91,108 shares, compared to its average volume of 990,521. The business's 50 day simple moving average is $129.55 and its two-hundred day simple moving average is $161.31. The stock has a market cap of $6.69 billion, a PE ratio of 908.97, a P/E/G ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $2.27 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Finally, TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).